← Back to Search

Gas

Xenon MRI for Pulmonary Arterial Hypertension (Jupiter PH Trial)

Phase 2
Recruiting
Led By Sudarshan Rajagopal, MD, PhD
Research Sponsored by Bastiaan Driehuys
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Outpatients of either gender, Age 18-75
WHO functional class (FC) 2-3 symptoms with a diagnosis of group 1 PH
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Jupiter PH Trial Summary

This trial is studying how disease progression and treatment affects changes in gas exchange and blood flow in people with pulmonary arterial hypertension.

Who is the study for?
This trial is for adults aged 18-75 with Pulmonary Hypertension (PH), specifically those who are newly diagnosed or have started treatment within the last three months. Participants must be able to consent and follow the study schedule, and women of childbearing age need a negative pregnancy test before MRI scans. Those awaiting lung transplants can join too, but not if they have severe liver disease, heart issues, active cancer, sickle cell anemia or conditions preventing MRI use.Check my eligibility
What is being tested?
The trial is testing how a type of imaging called Xenon 129 Magnetic Resonance Imaging (MRI) can show changes in lung function and blood flow in patients with different types of Pulmonary Hypertension. It aims to understand how these images change with disease progression or after starting treatment.See study design
What are the potential side effects?
Since this trial involves MRI scanning using hyperpolarized Xenon gas rather than drug interventions, typical side effects associated with medications may not apply. However, there might be risks related to lying still during the scan or reactions to inhaling Xenon gas.

Jupiter PH Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 75 years old.
Select...
My pulmonary hypertension symptoms are moderate.
Select...
I have not started treatment or started it within the last 3 months.
Select...
I have been diagnosed with a specific type of high blood pressure in my lungs.
Select...
I am on the waiting list for a lung transplant.

Jupiter PH Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Red Blood Cell Signal from Xenon MRI
pulmonary vascular remodeling

Jupiter PH Trial Design

2Treatment groups
Experimental Treatment
Group I: following pulmonary arterial hypertension subjectsExperimental Treatment1 Intervention
Following pulmonary arterial hypertension subjects upto 24 months
Group II: end-stage pulmonary hypertension .Experimental Treatment1 Intervention
subjects with end-stage PH that currently on the waitlist for lung transplant

Find a Location

Who is running the clinical trial?

Bastiaan DriehuysLead Sponsor
13 Previous Clinical Trials
1,007 Total Patients Enrolled
Sudarshan Rajagopal, MD, PhDPrincipal InvestigatorDuke University
3 Previous Clinical Trials
56 Total Patients Enrolled

Media Library

129Xe Hyperpolarized (Gas) Clinical Trial Eligibility Overview. Trial Name: NCT04991454 — Phase 2
Pulmonary Hypertension Research Study Groups: end-stage pulmonary hypertension ., following pulmonary arterial hypertension subjects
Pulmonary Hypertension Clinical Trial 2023: 129Xe Hyperpolarized Highlights & Side Effects. Trial Name: NCT04991454 — Phase 2
129Xe Hyperpolarized (Gas) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04991454 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment actively seeking out participants?

"The data being hosted on clinicaltrials.gov reveals this medical experiment is actively enrolling patients, with its first posting dating back to September 1st 2021 and the most recent change occurring on November 15th 2022."

Answered by AI

What detrimental effects might patients experience from using this treatment?

"Based on the Phase 2 trial data available, Power has determined that this treatment can be considered a moderate risk with a score of 2."

Answered by AI

Is my eligibility sufficient to join this medical study?

"For this clinical trial, 60 individuals suffering from pulmonary arterial hypertension and aged between 18 to 75 are being admitted. Specific enrolment criteria include: outpatients of either gender; prerequisite for lung transplantation; PAH diagnosis as demonstrated by right heart catheterization (mPAP ≥25 mmHg, PVR≥3 WU, PCWP ≤15mmHg); willingness to provide informed consent and comply with the protocol schedule; women that have not yet entered menopause must pass a urine pregnancy test before MRI."

Answered by AI

Does this medical trial accept individuals below fifty years old as participants?

"This medical research is seeking volunteers aged 18 and above, yet below 75 years of age."

Answered by AI

What is the overall participant tally for this clinical experiment?

"Correct. According to the data on clinicaltrials.gov, this medical trial is actively recruiting patients who meet its criteria. The study was initially posted on September 1st 2021 and has since been updated in November 15th 2022 with a total of 60 participants required from one location."

Answered by AI
~29 spots leftby Aug 2026